Follicular Lymphoma - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 542 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Follicular Lymphoma - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Follicular Lymphoma - Pipeline Review, H1 2016', provides an overview of the Follicular Lymphoma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Follicular Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Follicular Lymphoma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Follicular Lymphoma
- The report reviews pipeline therapeutics for Follicular Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Follicular Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses Follicular Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Follicular Lymphoma

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Follicular Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Follicular Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
Introduction 6
Follicular Lymphoma Overview 7
Therapeutics Development 8
Follicular Lymphoma - Therapeutics under Development by Companies 10
Follicular Lymphoma - Therapeutics under Investigation by Universities/Institutes 14
Follicular Lymphoma - Pipeline Products Glance 15
Follicular Lymphoma - Products under Development by Companies 18
Follicular Lymphoma - Products under Investigation by Universities/Institutes 24
Follicular Lymphoma - Companies Involved in Therapeutics Development 25
Follicular Lymphoma - Therapeutics Assessment 76
Drug Profiles 91
Follicular Lymphoma - Recent Pipeline Updates 303
Follicular Lymphoma - Dormant Projects 520
Follicular Lymphoma - Discontinued Products 523
Follicular Lymphoma - Product Development Milestones 524
Appendix 532

List of Tables

Number of Products under Development for Follicular Lymphoma, H1 2016 17
Number of Products under Development for Follicular Lymphoma - Comparative Analysis, H1 2016 18
Number of Products under Development by Companies, H1 2016 19
Number of Products under Development by Companies, H1 2016 (Contd..1) 20
Number of Products under Development by Companies, H1 2016 (Contd..2) 21
Number of Products under Development by Companies, H1 2016 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H1 2016 23
Comparative Analysis by Late Stage Development, H1 2016 24
Comparative Analysis by Clinical Stage Development, H1 2016 25
Comparative Analysis by Early Stage Development, H1 2016 26
Products under Development by Companies, H1 2016 27
Products under Development by Companies, H1 2016 (Contd..1) 28
Products under Development by Companies, H1 2016 (Contd..2) 29
Products under Development by Companies, H1 2016 (Contd..3) 30
Products under Development by Companies, H1 2016 (Contd..4) 31
Products under Development by Companies, H1 2016 (Contd..5) 32
Products under Investigation by Universities/Institutes, H1 2016 33
Follicular Lymphoma - Pipeline by AbbVie Inc., H1 2016 34
Follicular Lymphoma - Pipeline by Affimed GmbH , H1 2016 35
Follicular Lymphoma - Pipeline by Bayer AG, H1 2016 36
Follicular Lymphoma - Pipeline by BeiGene, Ltd., H1 2016 37
Follicular Lymphoma - Pipeline by Bio-Path Holdings, Inc., H1 2016 38
Follicular Lymphoma - Pipeline by Biocon Limited, H1 2016 39
Follicular Lymphoma - Pipeline by Biogenomics Limited, H1 2016 40
Follicular Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016 41
Follicular Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2016 42
Follicular Lymphoma - Pipeline by Celgene Corporation, H1 2016 43
Follicular Lymphoma - Pipeline by Celldex Therapeutics, Inc., H1 2016 44
Follicular Lymphoma - Pipeline by Celltrion, Inc., H1 2016 45
Follicular Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H1 2016 46
Follicular Lymphoma - Pipeline by Coherus BioSciences, Inc., H1 2016 47
Follicular Lymphoma - Pipeline by CTI BioPharma Corp., H1 2016 48
Follicular Lymphoma - Pipeline by Curis, Inc., H1 2016 49
Follicular Lymphoma - Pipeline by Dynavax Technologies Corporation, H1 2016 50
Follicular Lymphoma - Pipeline by Eisai Co., Ltd., H1 2016 51
Follicular Lymphoma - Pipeline by EpiZyme, Inc., H1 2016 52
Follicular Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 53
Follicular Lymphoma - Pipeline by Genentech, Inc., H1 2016 54
Follicular Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2016 55
Follicular Lymphoma - Pipeline by GlaxoSmithKline Plc, H1 2016 56
Follicular Lymphoma - Pipeline by Hutchison MediPharma Limited, H1 2016 57
Follicular Lymphoma - Pipeline by Immune Design Corp., H1 2016 58
Follicular Lymphoma - Pipeline by ImmunoGen, Inc., H1 2016 59
Follicular Lymphoma - Pipeline by Immunomedics, Inc., H1 2016 60
Follicular Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016 61
Follicular Lymphoma - Pipeline by Johnson & Johnson, H1 2016 62
Follicular Lymphoma - Pipeline by Juno Therapeutics Inc., H1 2016 63
Follicular Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 64
Follicular Lymphoma - Pipeline by Kite Pharma, Inc., H1 2016 65
Follicular Lymphoma - Pipeline by Les Laboratoires Servier SAS, H1 2016 66
Follicular Lymphoma - Pipeline by MedImmune, LLC, H1 2016 67
Follicular Lymphoma - Pipeline by Medivation, Inc., H1 2016 68
Follicular Lymphoma - Pipeline by MEI Pharma, Inc., H1 2016 69
Follicular Lymphoma - Pipeline by Merck & Co., Inc., H1 2016 70
Follicular Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 71
Follicular Lymphoma - Pipeline by Mirati Therapeutics Inc., H1 2016 72
Follicular Lymphoma - Pipeline by MorphoSys AG, H1 2016 73
Follicular Lymphoma - Pipeline by Nordic Nanovector ASA, H1 2016 74
Follicular Lymphoma - Pipeline by Novartis AG, H1 2016 75
Follicular Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 76
Follicular Lymphoma - Pipeline by Pfizer Inc., H1 2016 77
Follicular Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2016 78
Follicular Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2016 79
Follicular Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H1 2016 80
Follicular Lymphoma - Pipeline by Sandoz International GmbH, H1 2016 81
Follicular Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2016 82
Follicular Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 83
Follicular Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2016 84
Assessment by Monotherapy Products, H1 2016 85
Assessment by Combination Products, H1 2016 86
Number of Products by Stage and Target, H1 2016 88
Number of Products by Stage and Mechanism of Action, H1 2016 93
Number of Products by Stage and Route of Administration, H1 2016 97
Number of Products by Stage and Molecule Type, H1 2016 99
Follicular Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016 312
Follicular Lymphoma - Dormant Projects, H1 2016 529
Follicular Lymphoma - Dormant Projects (Contd..1), H1 2016 530
Follicular Lymphoma - Dormant Projects (Contd..2), H1 2016 531
Follicular Lymphoma - Discontinued Products, H1 2016 532